Nanobiotix H1 basic loss EUR0.70 per share, cash runway into 2029

Nanobiotix reported a first-half 2026 net loss of EUR34.3 million, or EUR0.70 per share, compared with a loss of EUR5.4 million a year earlier. Cash and equivalents stood at EUR110.9 million at June 30, extended by an oversubscribed EUR86 million follow-on offering. The company highlighted early clinical data from its JNJ-1900 (NBTXR3) program in NSCLC and received FDA clearance for a Phase 3 protocol amendment in head and neck cancer.